Register now

To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

Login/Register
EN FR

PrSymbicort® budesonide/formoterol fumarate dihydrate

Welcome to
SYMBICORT

A website for Canadian pharmacists
Download SYMBICORT TURBUHALER Action Plan Download Starting SYMBICORT Guide
SYMBICORT TURBUHALER: The #1 dispensed ICS/LABA1

SYMBICORT TURBUHALER:

The #1 dispensed
ICS/LABA1

The #1
dispensed
ICS/LABA1

Support your patients with asthma or moderate to severe COPD by learning more about SYMBICORT® TURBUHALER®

In Canada, SYMBICORT TURBUHALER is indicated for2

The treatment of asthma in patients 12 years and older with reversible obstructive airways disease.

In Canada, SYMBICORT 200 TURBUHALER and SYMBICORT FORTE TURBUHALER are indicated for2

The maintenance treatment of moderate to severe COPD including chronic bronchitis and emphysema in patients with persistent symptoms and a history of exacerbations, where the use of a combination product is considered appropriate.

Stay informed on the latest CTS guidelines to help support your patients

Review the CTS Summary Booklet for guidance updates on budesonide/formoterol therapy in mild and moderate asthma, and encourage your patients to speak with a doctor if their current asthma treatment plan is not working.

Learn more about SYMBICORT TURBUHALER and access resources
designed to help you support your patients below.

COPD: chronic obstructive pulmonary disease; CTS: Canadian Thoracic Society; ICS: inhaled corticosteroid; LABA: long-acting beta2-adrenergic agonist.

 

References:

  • Data on file. AstraZeneca Canada Inc. April 15, 2024.
  • Symbicort® Turbuhaler® Product Monograph. AstraZeneca Canada Inc. February 8, 2021.
Back to Top